Diagnostic and Therapeutic Potential of Extracellular Vesicles


Posted: 2021-10-11 19:00:00
Technol Cancer Res Treat . Jan-Dec 2021;20:15330338211041203. doi: 10.1177/15330338211041203. Affiliations Expand Affiliations 1 Institute for Immunity and Transplantation, 158423Stem Cell Biology and Regenerative Medicine, School of Medicine, 6429Stanford University, Palo Alto, California, USA. 2 School of Medicine, 6429Stanford University, Palo Alto, California, USA. Item in Clipboard Sai Priyanka Kodam et al. Technol Cancer Res Treat. Jan-Dec 2021. Show details Display options Display options Format Technol Cancer Res Treat . Jan-Dec 2021;20:15330338211041203. doi: 10.1177/15330338211041203. Affiliations 1 Institute for Immunity and Transplantation, 158423Stem Cell Biology and Regenerative Medicine, School of Medicine, 6429Stanford University, Palo Alto, California, USA. 2 School of Medicine, 6429Stanford University, Palo Alto, California, USA. Item in Clipboard CiteDisplay options Display options Format Abstract Extracellular vesicles (EVs) are naturally phospholipid enclosed nanovesicles released by many cells in the body. They are stable in circulation, have low immunogenicity, and act as carriers for functionally active biological molecules. They interact with target organs and bind to the receptors. Their target specificity is important to use EVs as noninvasive diagnostic and prognostic tools. EVs play a vital role in normal physiology and cellular communication. They are known to protect their cargo from degradation, which makes them important drug carriers for targeted drug delivery. Using EVs with markers and tracking their path in systemic circulation can be revolutionary in using them as diagnostic tools. We will discuss the scope of this in this paper. Although there are limitations in EVs isolation and storage, their high biocompatibility will fuel more innovations to overcome these challenges. Keywords: artificial intelligence; cancer; cytokine; drug delivery; exosomes; extracellular vesicles; innovative technologies; regenerative medicine.

参考サイト PubMed: exsome



バイオクイックニュース日本語版:エクソソーム特集

バイオクイックニュース日本語版
9月 18, 2019 バイオアソシエイツ

創傷治療治験中のペプチド変異体が、心臓発作の『バイスタンダー効果』による損傷を防御する可能性。研究グループはエクソソームによる防御ペプチドの送達を検討中。

健康な心筋組織を保護することで損傷を減らす心臓発作の直後に服用できる薬があると想像して欲しい。 心臓発作が起きた場合、心臓の専門医は、「時は筋肉なり」と言うと、バージニア工科大学カリリオン心臓医療センター・フラリン生物医学研究所のディレクターであるRobert Gourdie博士(写真)は語った。 血流によって酸素が供給されないと、心臓細胞はすぐに死ぬ。…

ゲスト 618人 と メンバー 6人 がオンラインです